Today is Tuesday, March 10, 2020 and here’s your daily small cap valuation.
OncoCyte Corporation (NYSE: OCX) is a small-cap stock that could have a lot of potential. But it’s hard to value smaller companies like this. Conventional valuation metrics like price-to-earnings (P/E) ratio, profit margin, and return on equity (ROE) may not be available for them.
To get a sense of OncoCyte Corporation’s true valuation, let’s compare it to its industry peers — and to itself one year ago. We’ll look at four small cap valuation metrics…
Price-to-Book Value (P/B) Ratio
OncoCyte Corporation’s price-to-book value (P/B) ratio of 4.356 is 29.50% lower than its industry average of 6.179. That’s good. A low P/B ratio indicates that the company has a solid balance sheet — and that based on its balance sheet, the stock is trading for unusually cheap.
Free Cash Flow Yield (FCF/Enterprise Value)
OncoCyte Corporation’s free cash flow yield (FCF/EV) of -14.51% is 370.71% lower than its industry average of 5.36%. That’s not good. This metric compares free cash flow (the amount of cash left over after all expenses and capital expenditures have been paid) with enterprise value (a comprehensive alternative to market cap that includes cash and debt).
A low free cash flow yield indicates that a company is performing inefficiently — or that it’s struggling with the debt on its books.
Earnings per Share (EPS) Growth
OncoCyte Corporation has grown its earnings per share (EPS) by 11.36% in the last year. That’s good. Many smaller, newer companies have negative earnings for a few years, but that’s okay as long as earnings are going up over time.
Gross Margin Growth
OncoCyte Corporation’s gross margin is undefined. That’s not good. This may indicate that the company has failed to file an income statement properly. We have to fault it for this.
OncoCyte Corporation scored favorably on 2 of our 4 valuation metrics. With this in mind, we believe the stock is appropriately valued.
Editor’s Note: We’ve been keeping an eye on a set of small-cap stocks that are a better value than OncoCyte Corporation. These stocks have the potential for bigger gains — and they’re far less risky than the speculative small caps many investors gamble on. Enter your email below to learn more.